Percutaneous drug absorption in the newborn: hazards and uses

Area of Science:

• Neonatal dermatology
• Pharmacokinetics in infants
• Drug absorption and toxicology

Background:

• Newborn skin barrier function is immature, increasing permeability to external agents.
• Skin immaturity is the primary determinant of percutaneous absorption in neonates.
• Immature epidermal development in early neonatal periods leads to significant drug permeability.

Purpose of the Study:

• To highlight the risks associated with topical agent absorption in newborn infants.
• To explore the potential benefits of enhanced percutaneous absorption for drug delivery in neonates.
• To emphasize the need for specialized transdermal drug delivery systems for infants.

Main Methods:

• Review of existing literature on neonatal skin permeability.
• Analysis of the physiological factors influencing percutaneous absorption in newborns.
• Case study examples illustrating consequences of topical agent absorption.

Main Results:

• Percutaneous absorption of topical agents can lead to unrecognized toxic systemic effects, potentially causing severe illness or death.
• Immature skin in premature infants is highly permeable, making them vulnerable to adverse drug reactions.
• Theophylline absorption via topical application can maintain therapeutic blood levels for up to 3 days.

Conclusions:

• Topical applications on newborn skin require careful consideration due to potential hazardous absorption.
• Infant skin's permeability presents an opportunity for alternative drug administration routes.
• Development of infant-specific transdermal drug delivery systems is crucial for safe and effective neonatal therapy.